Cellectar raises ~$35M via stock/warrant offering; reports positive 12-mo Phase 2b WM data

Cellectar Biosciences, Inc.

Gross proceeds ~$35M; issued 1.6M registered shares, 2.1M unregistered, and warrants for 9.5M+13.2M shares.
Phase 2b CLOVER WaM: 83.6% ORR, 61.8% MRR, median DoR 17.8 months in r/r WM.
BTKi-exposed: 64.1% MRR, median PFS 15.9 mo; BTKi-refractory: 63.6% MRR, median PFS 14.8 mo.
Nantahala gets board seat; warrants exercisable upon stockholder approval at $2.65.
Proceeds to support Phase 3 trial of iopofosine I 131 for Waldenström macroglobulinemia.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Cellectar Biosciences, Inc. entered into Management Purchase Agreement with certain members of the executive management team of the Company (effective 2026-05-04).

Action: entry
Agreement: equity purchase
Counterparty: certain members of the executive management team of the Company
Effective: 2026-05-04

Exact text from the filing

pursuant to an additional securities purchase agreement with certain members of the executive management team of the Company (the “Management Purchase Agreement”

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Cellectar Biosciences, Inc. entered into Investor Purchase Agreement with certain institutional investors (effective 2026-05-04).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional investors
Effective: 2026-05-04

Exact text from the filing

On May 4, 2026, Cellectar Biosciences, Inc., a Delaware corporation (the “Company”) entered into a securities purchase agreement with certain institutional investors (the “Investor Purchaser Agreement”)

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Cellectar Biosciences, Inc. entered into Placement Agency Agreement with Ladenburg Thalmann & Co. Inc. (effective 2026-05-04).

Action: entry
Agreement: underwriting
Counterparty: Ladenburg Thalmann & Co. Inc.
Effective: 2026-05-04

Exact text from the filing

on May 4, 2026, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Ladenburg Thalmann & Co. Inc. (the “Placement Agent”)

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Cellectar Biosciences, Inc. entered into Registration Rights Agreement with certain investors (effective 2026-05-04).

Action: entry
Counterparty: certain investors
Effective: 2026-05-04

Exact text from the filing

on May 4, 2026, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with certain investors

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

Cellectar Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-057460

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.